MX362939B - Derivados de (aza-)isoquinolinona. - Google Patents

Derivados de (aza-)isoquinolinona.

Info

Publication number
MX362939B
MX362939B MX2015001545A MX2015001545A MX362939B MX 362939 B MX362939 B MX 362939B MX 2015001545 A MX2015001545 A MX 2015001545A MX 2015001545 A MX2015001545 A MX 2015001545A MX 362939 B MX362939 B MX 362939B
Authority
MX
Mexico
Prior art keywords
aza
isoquinolinone derivatives
diseases
isoquinolinone
derivatives
Prior art date
Application number
MX2015001545A
Other languages
English (en)
Other versions
MX2015001545A (es
Inventor
Dorsch Dieter
Buchstaller Hans-Peter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2015001545A publication Critical patent/MX2015001545A/es
Publication of MX362939B publication Critical patent/MX362939B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos de la fórmula I (ver Fórmula) en donde R1, X, Y y n tienen los significados indicados en la reivindicación 1, son inhibidores de Tankirasa y se pueden emplear, inter alia, para el tratamiento de enfermedades tales como cáncer, enfermedades cardiovasculares, lesión del sistema nervioso central y diferentes formas de inflamación.
MX2015001545A 2012-08-08 2013-07-12 Derivados de (aza-)isoquinolinona. MX362939B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12005752 2012-08-08
PCT/EP2013/002085 WO2014023390A2 (en) 2012-08-08 2013-07-12 (aza-)isoquinolinone derivatives

Publications (2)

Publication Number Publication Date
MX2015001545A MX2015001545A (es) 2015-05-11
MX362939B true MX362939B (es) 2019-02-27

Family

ID=48793165

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001545A MX362939B (es) 2012-08-08 2013-07-12 Derivados de (aza-)isoquinolinona.

Country Status (23)

Country Link
US (1) US9376433B2 (es)
EP (1) EP2882714B1 (es)
JP (2) JP6247294B2 (es)
KR (1) KR102083154B1 (es)
CN (1) CN104507912B (es)
AR (1) AR092366A1 (es)
AU (1) AU2013301870B2 (es)
BR (1) BR112015002601A2 (es)
CA (1) CA2881330C (es)
DK (1) DK2882714T3 (es)
ES (1) ES2773272T3 (es)
HR (1) HRP20200180T1 (es)
HU (1) HUE047608T2 (es)
IL (1) IL237072B (es)
LT (1) LT2882714T (es)
MX (1) MX362939B (es)
PL (1) PL2882714T3 (es)
PT (1) PT2882714T (es)
RS (1) RS59921B1 (es)
RU (1) RU2654216C2 (es)
SG (1) SG11201500732TA (es)
SI (1) SI2882714T1 (es)
WO (1) WO2014023390A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2942847B2 (ja) 1990-06-22 1999-08-30 ダイセル化学工業株式会社 液晶性ポリマーフィルムの製造装置とそれを用いた液晶性ポリマーフィルムの製造方法
EP2822656B1 (en) 2012-03-07 2016-10-19 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
WO2014087165A1 (en) * 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors
US9611223B2 (en) 2013-09-11 2017-04-04 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
AU2015245786B2 (en) * 2014-04-10 2018-03-15 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. Analogues of 4H-pyrazolo[1,5-a]benzimidazole compound as PARP inhibitors
CN105153156B (zh) * 2015-09-22 2017-07-28 徐峰 一种4‑苯基‑2,7‑萘啶‑1（2h）‑酮的制备方法
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
US10759795B2 (en) 2016-03-15 2020-09-01 Purdue Research Foundation Aza-A-ring indenoisoquinoline topoisomerase I poisons
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
CN110167936A (zh) 2016-12-22 2019-08-23 珀杜研究基金会 氮杂茚并异喹啉化合物及其用途
US10899733B2 (en) 2017-08-23 2021-01-26 Oregon Health & Science University Inhibitors of PARPs that catalyze mono-ADP-ribosylation
RU2709928C1 (ru) * 2019-02-21 2019-12-24 Федеральное государственное бюджетное научное учреждение "Институт природно-технических систем" (ИПТС) Датчик удельной электропроводности
JPWO2024029583A1 (es) * 2022-08-05 2024-02-08
GB2634228A (en) * 2023-10-02 2025-04-09 Duke Street Bio Ltd PARP1 inhibitor compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
WO1999011622A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
WO1999018077A1 (en) 1997-10-02 1999-04-15 Eisai Co., Ltd. Fused pyridine derivatives
JP3989102B2 (ja) * 1997-10-02 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリジン誘導体
OA11591A (en) * 1998-08-11 2004-07-30 Pfizer Prod Inc Substituted 1,8-naphthyridin-4(H)-ones as phosphodiesterase 4 inhibitors.
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2005075432A1 (ja) * 2004-02-06 2005-08-18 Chugai Seiyaku Kabushiki Kaisha １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用
US7772180B2 (en) * 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2009008099A (es) 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
SI2134691T1 (sl) 2007-03-08 2012-06-29 Janssen Pharmaceutica Nv Derivati kvinolina kot PARP in TANK inhibitorji
TWI499418B (zh) 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉－１（２ｈ）－酮衍生物
FR2956816B1 (fr) 2010-03-01 2012-05-18 Univ Joseph Fourier Utilisation de quinolones pour la preparation de medicaments, nouvelles quinolones et leur procede de synthese
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2822656B1 (en) * 2012-03-07 2016-10-19 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US20130311482A1 (en) 2012-05-17 2013-11-21 Tagged, Inc. Multi-user timeline for facilitating social discovery in social networking environments

Also Published As

Publication number Publication date
AU2013301870B2 (en) 2017-04-27
IL237072B (en) 2018-11-29
WO2014023390A2 (en) 2014-02-13
MX2015001545A (es) 2015-05-11
SG11201500732TA (en) 2015-02-27
RS59921B1 (sr) 2020-03-31
JP6247294B2 (ja) 2017-12-13
US9376433B2 (en) 2016-06-28
LT2882714T (lt) 2020-03-10
JP2018008974A (ja) 2018-01-18
HUE047608T2 (hu) 2020-05-28
EP2882714B1 (en) 2019-11-13
RU2015107702A (ru) 2016-09-27
HRP20200180T1 (hr) 2020-05-01
RU2654216C2 (ru) 2018-05-17
KR20150041649A (ko) 2015-04-16
HK1209106A1 (en) 2016-03-24
WO2014023390A3 (en) 2014-04-10
EP2882714A2 (en) 2015-06-17
KR102083154B1 (ko) 2020-03-02
JP6333450B2 (ja) 2018-05-30
CA2881330A1 (en) 2014-02-13
PL2882714T3 (pl) 2020-02-28
DK2882714T3 (da) 2020-01-20
CN104507912A (zh) 2015-04-08
PT2882714T (pt) 2020-02-19
AU2013301870A1 (en) 2015-03-19
CN104507912B (zh) 2016-09-28
CA2881330C (en) 2020-07-21
BR112015002601A2 (pt) 2017-07-04
US20150210686A1 (en) 2015-07-30
JP2015524450A (ja) 2015-08-24
ES2773272T3 (es) 2020-07-10
SI2882714T1 (sl) 2020-03-31
AR092366A1 (es) 2015-04-15

Similar Documents

Publication Publication Date Title
MX362939B (es) Derivados de (aza-)isoquinolinona.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MX2014013090A (es) Derivados de pirrolotriazinona.
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
MX2016001136A (es) Derivados de oxoquinazolinil-butanamida.
PH12014501581A1 (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
NZ700928A (en) Dna-pk inhibitors
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
MY177344A (en) Compounds and their methods of use
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MX2016014436A (es) Derivados de heterociclil-butanamida.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MX2016001134A (es) Derivados 1,3-disustituidos de ciclopentano.
MX366140B (es) Derivados de urea de piperidinas.
MX376090B (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas.
MX2016008042A (es) Derivados de imidazopirazinona.
MX2014006015A (es) Derivados de 3-fenil-isoquinolin-1 (2h) -ona como inhibidores de parp-1.
MX2018005515A (es) Derivados de 1,4-dicarbonil-piperidilo.
MX2015016760A (es) Derivados de ftalazina.
MX2016001934A (es) Derivados de ciclopentilamina 3-sustituidos.

Legal Events

Date Code Title Description
FG Grant or registration